Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Phase 4 Completed 20 enrolled University of Cincinnati

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.

Timeline

Start: 2006-11
Primary completion: 2008-07
Completion: 2008-09

Publications

Baughman RP, Judson MA, Lower EE, Highland K, Kwon S, Craft N, Engel PJ. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):110-20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iloprost	Other / unclassified	2.5 mg	Inhaled
Subject	Iloprost	Other / unclassified	5 mg	Inhaled

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Summary

Timeline

Publications

Drugs

Indications